The partners will use Adaptive's ClonoSeq assay to assess minimal residual disease in several of Amgen's hematology drug development programs.
The UK is partnering with pharmaceutical companies to sequence and analyze DNA samples from UK Biobank participants.
The project is funded with £50 million from the UK government, £50 million from the Wellcome Trust, and £100 million from four pharmaceutical firms.
Consenting participants will have their deidentified sequence data used for research and will also have the chance to learn if they have clinically actionable results.
The partners are both "investing heavily" in the study and will have access to the data and to new technologies and interventions.
The companies will develop analytics tools and leverage the Syapse Learning Health Network in an effort to shorten the time to market for new cancer therapies.
In PNAS this week: core Pseudomonas aeruginosa genome, study of ancient Paget's disease of the bone, and more.
In Science this week: high-resolution map of human genetic recombination, and more.
Results from two GWAS studies suggest that 15-LO inhibitors could be a viable treatment for nasal polyps and chronic rhinosinusitis.
The firm is using collaborations to access the large, diverse cohorts it needs to support its goal of commercializing its SomaScan system as a clinical platform.
A South African university has told the Wellcome Sanger Institute to return DNA samples it has from indigenous African communities, The Times reports.
The University of California, Berkeley's Rasmus Nielsen and Xinzhu Wei have retracted their CCR5 gene paper due to a technical artifact.
University of Virginia researchers are exploring a genetic risk test to gauge type 1 diabetes risk, NPR reports.
In PNAS this week: researchers compare two high-grade neuroendocrine lung cancers, height among ancient Europeans, and more.